BenevolentAI
our precision medicine approaches are applied to multiple stages of our pipeline and can support activities precision medicine enabled target indication mapping additional indications a target or drug approved or in development through the cation of additional disease indications address additional unmet need the value of a target or drug identifying key patient cohorts and responders for drugs clinical development increase probability of success improve outcomes for patients cation of patient cohorts responders trial design patient outcomes for each indication | BenevolentAI
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
63 of 74
Related slides by other companies
Progenity
IPO
June 2020
precision medicine disruptive platform and pipeline progenity | Progenity
Exscientia
Investor Presentation
March 2024
trials expansion of precision medicine platform a i | Exscientia
Exscientia
Investor Presentation
June 2022
patient first is a learning process | Exscientia
Neumora Therapeutics
IPO
September 2023
precision medicine approach can be leveraged to maximize the value of our programs | Neumora Therapeutics
Other recent decks by BenevolentAI
See all presentations (10 decks)
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io